Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Alps Advisors Inc.

Alps Advisors Inc. decreased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 12.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,204 shares of the biotechnology company’s stock after selling 9,293 shares during the quarter. Alps Advisors Inc.’s holdings in Arrowhead Pharmaceuticals were worth $2,249,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Virtus Advisers LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $34,000. Salomon & Ludwin LLC acquired a new stake in Arrowhead Pharmaceuticals in the third quarter worth $34,000. Nisa Investment Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $52,000. Finally, Daiwa Securities Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 883.3% during the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 3,763 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling

In other news, CEO Christopher Richard Anzalone sold 130,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the completion of the sale, the chief executive officer owned 3,971,255 shares in the company, valued at approximately $273,420,906.75. This represents a 3.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James C. Hamilton sold 40,164 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider owned 171,958 shares in the company, valued at $10,852,269.38. The trade was a 18.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 510,836 shares of company stock worth $33,603,060 over the last three months. Corporate insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ARWR shares. B. Riley Financial lifted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday. Finally, Chardan Capital lifted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $62.92 on Wednesday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $76.76. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The firm has a 50-day moving average of $67.09 and a two-hundred day moving average of $44.49. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of 41.12 and a beta of 1.21.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm’s revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. As a group, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.